Log in

Relevant bibliographies by topics / Lurasidone Hcl / Journal articles

To see the other types of publications on this topic, follow the link: Lurasidone Hcl.

Journal articles on the topic 'Lurasidone Hcl'

Author: Grafiati

Published: 4 June 2025

Last updated: 14 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 16 journal articles for your research on the topic 'Lurasidone Hcl.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

El-Beshlawy, Menna M., Ahmed Barhoum, and Fatehy M. Abdel-Haleem. "Nanomolar detection of lurasidone hydrochloride in pharmaceutical formulations (Serodopamoun®) and spiked urine using a PVC/imprinted polymer/MWCNTs layer deposited onto polyaniline-coated screen-printed electrodes." RSC Advances 14, no. 53 (2024): 39769–78. https://doi.org/10.1039/d4ra07098d.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Mittal, Ankit, Manish Yadav, Dinesh Choudhary, and Birendra Shrivastava. "ENHANCEMENT OF SOLUBILITY OF LURASIDONE HCL USING SOLID DISPERSION TECHNIQUE." International Journal of Research in Ayurveda & Pharmacy 5, no. 5 (2014): 632–37. http://dx.doi.org/10.7897/2277-4343.055129.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Simranjeet, Singh Muskan Sood Anu Jindal* Rajmeet Singh Satvinder Kaur Jaswinder Singh Shaveta Bhardwaj. "Analytical Method Validation of Tablet Dosage Form of Lurasidone HCl." International Journal in Pharmaceutical Sciences 1, no. 11 (2023): 240–45. https://doi.org/10.5281/zenodo.10112998.

Full text

Abstract:

This research is mainly focused on development of an Excellent Gradient method by reverse phase - high performance liquid chromatography (RP-HPLC) using UV Visible Detector. The main objective of method validation of Lurasidone HCl as a tablet dosage form is to validate the method as in-house method. As this tablet dosage form is not registered in any of Pharmacopeia, so the method is developed and validated for further studies. The sample is analyzed by RP-HPLC using octadecylsilane (C18) column (Inertsil LC-GC) as stationary phase with UV-Visible detector. The 'Gradient Method' is used as in

APA, Harvard, Vancouver, ISO, and other styles

4

Simranjeet, Singh Muskan Sood Anu Jindal* Rajmeet Singh Satvinder Kaur Jaswinder Singh Shaveta Bhardwaj. "Analytical Method Validation of Tablet Dosage Form of Lurasidone HCl." International Journal in Pharmaceutical Sciences 1, no. 11 (2023): 240–45. https://doi.org/10.5281/zenodo.10113218.

Full text

Abstract:

This research is mainly focused on development of an Excellent Gradient method by reverse phase - high performance liquid chromatography (RP-HPLC) using UV Visible Detector. The main objective of method validation of Lurasidone HCl as a tablet dosage form is to validate the method as in-house method. As this tablet dosage form is not registered in any of Pharmacopeia, so the method is developed and validated for further studies. The sample is analyzed by RP-HPLC using octadecylsilane (C18) column (Inertsil LC-GC) as stationary phase with UV-Visible detector. The 'Gradient Method

APA, Harvard, Vancouver, ISO, and other styles

5

Vijaya Sri, K., M. Shiva Kumar, and A. Sravani. "RAPID RP-HPLC METHOD DEVELOPMENT AND VALIDATION OF LURASIDONE HYHROCHLORIDE IN BULK AND TABLET FORM." INDIAN DRUGS 54, no. 01 (2017): 28–34. http://dx.doi.org/10.53879/id.54.01.10572.

Full text

Abstract:

The RP-HPLC were developed and validated for the estimation of lurasidone HCl as per ICH guidelines. A simple, fast, accurate and precise RP-HPLC method was developed by using methanol: water containing 0.01% ortho phosphoric acid in the ratio of 70:30 (V/V). The method was developed in Eclipse C18 column (100 mm × 4.6 mm, 3.5 μm particle size). The method was found to be linear in the range of 2.5- 15µg/mL with a correlation coefficient value of 0.999. The accuracy studies of RP-HPLC method was performed at three different levels, i.e., 50%, 100%, and 150% and recovery was found to be in the

APA, Harvard, Vancouver, ISO, and other styles

6

Suneetha, A., K. Manasa, and S. Lakshmi Sindhura. "Stability Indicating RP-HPLC Method for Determination and Validation of Lurasidone HCL in Bulk and Pharmaceutical Dosage Forms." Journal of Pharmaceutical Research 14, no. 1 (2015): 15. http://dx.doi.org/10.18579/jpcrkc/2015/14/1/78370.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Patel, Mrunali R., Rashmin B. Patel, Shivam D. Thakore, and Ajay B. Solanki. "Brain targeted delivery of lurasidone HCl via nasal administration of mucoadhesive nanoemulsion formulation for the potential management of schizophrenia." Pharmaceutical Development and Technology 25, no. 8 (2020): 1018–30. http://dx.doi.org/10.1080/10837450.2020.1772292.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Ramanjaneyulu, Siddabathuni, K. M. V. Narayana Rao, and Shyamala Pulipaka. "Assessment of Novel Stability-Indicating Technique-based HPLC Approach for One Genotoxic Impurity and Three Related Substance Impurities of Lurasidone Hydrochloride: Degradation Studies on Lurasidone Hydrochloride." Asian Journal of Chemistry 34, no. 7 (2022): 1825–34. http://dx.doi.org/10.14233/ajchem.2022.23783.

Full text

Abstract:

The present work communicates the selective quantification of a genotoxic impurity (P-LUH) and lurasidone hydrochloride (LUH) related compounds (I1-LUH, I2-LUH and I3-LUH) as potential impurities in the LUH active therapeutic ingredient using novel stability-indicating technique-based HPLC approach. The P-LUH, I1-LUH, I2-LUH and I3-LUH were separated on column Inerstil ODS 3V having length size of 250 mm, identification value of 4.6 mm and particle dimension of 5 μm. After that, a high sensitivity PDA detector at 231 nm was used to detect the signal of impurities. The method was thoroughly val

APA, Harvard, Vancouver, ISO, and other styles

9

Patel, Mitali H., Veenu P. Mundada, and Krutika K. Sawant. "Fabrication of solid lipid nanoparticles of lurasidone HCl for oral delivery: optimization, in vitro characterization, cell line studies and in vivo efficacy in schizophrenia." Drug Development and Industrial Pharmacy 45, no. 8 (2019): 1242–57. http://dx.doi.org/10.1080/03639045.2019.1593434.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

ARIRAHMAYANTI, I. GUSTI AYU EKA, I. GUSTI AYU INDAH ARDANI, and MUHAMAD SUHARDI. "GANGGUAN SKIZOAFEKTIF DENGAN KOMORBIDITAS DIABETES MELITUS : SEBUAH TINJAUAN PUSTAKA." KNOWLEDGE: Jurnal Inovasi Hasil Penelitian dan Pengembangan 4, no. 3 (2024): 96–106. https://doi.org/10.51878/knowledge.v4i3.3679.

Full text

Abstract:

The prevalence rate is that individuals with schizophrenia and schizoaffective disorder have more than twice the risk of developing type 2 diabetes mellitus (T2DM) compared to the general population. People on the schizophrenia spectrum are genetically predisposed to type II diabetes, accompanied by weight gain as a side effect of treatment, which is a risk factor for developing type 2 diabetes, which will worsen medical outcomes and mortality rates. This literature review involves 21 journal and book literature from the last 10 years regarding schizoaffective with comorbid diabetes mellitus.

APA, Harvard, Vancouver, ISO, and other styles

11

Komal, Rahevar* Dr. Mukesh R. Patel Dr. Kanu R. Patel. "DESIGN AND DEVELOPMENT OF SELF MICROEMULSIFYING DRUG DELIVERY SYSTEM OF LURASIDONE HCl." December 31, 2017. https://doi.org/10.5281/zenodo.2529309.

Full text

Abstract:

Objective: Lurasidone HCl is poorly water soluble drug. It should be come in to the BCS Class II drug. Hence oral Bioavailability of Lurasidone HCl is less (9-19%). To develop novel dosage foam of the self-Microemulsifying drug delivery systems (SMEDDS) for the Lurasidone HCl for enhancing its solubility hence the oral bioavailability. Methods: Solubility study was performed in different excipient and selected excipient on basis of solubility of Lurasidone HCl. Self microemulsion region was decided by preparing construction phase diagram. Drug excipient interaction study using FTIR. SMEDDS for

APA, Harvard, Vancouver, ISO, and other styles

12

Gattu, Manisha* Dr. M. Venkataramana Dr Rangu Nirmala. "ANALYTICAL METHOD DEVELOPMENT AND VALIDATION FOR THE DETERMINATION OF LURASIDONE HCL IN PHARMACEUTICAL DOSAGE FORM BY RP-HPLC." July 21, 2023. https://doi.org/10.5281/zenodo.8170995.

Full text

Abstract:

<em>A simple, accurate, precise and sensitive RP-HPLC assay method have been validated for the estimation of Lurasidone HCl in bulk and marketed pharmaceutical formulation.Lurasidone HCl is separated using Symmetry C18 ODS (4.6mm×150mm) 5µm particle size column and Methanol: Phosphate Buffer (0.05M-pH-4.8) (34:66) used as a mobile phase at a flow rate of 1.0ml/ minand effluent was detected at 315 nm. Here resolution was good, theoretical plate count and symmetry was appropriate. The retention time of Lurasidone HCl was found to be 2.248 minutes.Linearity was observed over concentra

APA, Harvard, Vancouver, ISO, and other styles

13

Tanushree, C* Gowrishankar Chandrakala DC. "APPLICATION OF FREEZE-DRYING TECHNIQUE IN THE DEVELOPMENT AND EVAULATION OF NANOSUSPENSION LOADED ODF OF ANTIPSYCHOTIC DRUG." December 12, 2022. https://doi.org/10.5281/zenodo.7428545.

Full text

Abstract:

<em>Lurasidone HCl is antipsychotic drug belonging to BCS class II drug used for the treatment of schizophrenia. It was initially approved by the U.S. Food and Drug Administration (FDA) for the treatment of adults with schizophrenia. Our study was aimed at increasing the solubility of Lurasidone HCl by formulating nanosuspension and then incorporating it into oral dissolving films which were prepared by freeze drying technique to enhance Solubility and stability of film, Bioavailability and patient compliance. Reducing of particle size is achieved by formulating nanosuspension by High Pressure

APA, Harvard, Vancouver, ISO, and other styles

14

Bhatt, Shailendra, Sumit Sharma, Jai Bharti Sharma, Manish Kumar, Ravinder Verma, and Deepak Kaushik. "Engineering of Lurasidone hydrochloride loaded niosomes for enhancing the antipsychotic potential for nasal administration." Current Nanomedicine 13 (January 17, 2023). http://dx.doi.org/10.2174/2468187313666230117163425.

Full text

Abstract:

Background: Drugs with high first-pass metabolism or that are susceptible to enzymatic degradation can be administered through the nasal route to avoid their degradation. Lurasidone exhibits less toxicity and side effects as compared to its sister drugs like risperidone, ziprasidone, clozapine, etc. Objectives: The present study aimed to develop Lurasidone loaded niosomes for nasal delivery. Methods: Lurasidone niosomes were developed by adapting the ether injection method and optimized using a central composite design. In vitro and in vivo studies were conducted using optimized formulation. R

APA, Harvard, Vancouver, ISO, and other styles

15

Macwan, Nikita, Hemil S. Patel, Rakesh K. Sharma, Nihali Jain, and Hemal Tandel. "Optimization of Lurasidone HCl-Loaded PLGA Nanoparticles for Intramuscular Delivery: Enhanced Bioavailability, Reduced Dosing Frequency, Pharmacokinetics, and Therapeutic Outcomes." ASSAY and Drug Development Technologies, December 27, 2023. http://dx.doi.org/10.1089/adt.2023.089.

Full text

APA, Harvard, Vancouver, ISO, and other styles

16

Sheth, Tulsi Sagar, and Falguni Acharya. "Optimizing similarity factor of in vitro drug release profile for development of early stage formulation of drug using linear regression model." Journal of Mathematics in Industry 11, no. 1 (2021). http://dx.doi.org/10.1186/s13362-021-00104-9.

Full text

Abstract:

AbstractThe objective of this article is to optimize the similarity factor within immediate release (IR) and modified release (MR) of in vitro drug release profiles. The least square method is used to minimize the difference between empirical and regression curve fitting data of in vitro IR/MR drug release profiles. An estimation of percentage drug release at intermediate timepoints has been done to improve the similarity factor $f_{2}$ f 2 using linear curve fit method. In this study linear regression model is used to analyze the similarity factor $f_{2}$ f 2 for Nitrofurantoin MR Capsules, V

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!